Cargando…

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases

Cardiovascular disease is the leading cause of mortality worldwide, affecting a wide range of patients at different stages across the cardiovascular continuum. Hypertension is one of the earliest risk factors in this continuum and can be controlled in most patients with currently available antihyper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strauss, Martin H., Hall, Alistair S., Narkiewicz, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397146/ https://www.ncbi.nlm.nih.gov/pubmed/34533690 http://dx.doi.org/10.1007/s10557-021-07248-1

Ejemplares similares

Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers
por: Chao, Chia-Ter
Publicado: (2011)

Treatment of heart failure with ACE inhibitors and beta-blockers: What is next? Aldosterone receptor antagonists?
por: van der Horst, Iwan C. C., et al.
Publicado: (2007)

Heart Rate and Cardiovascular Disease: An Alternative to Beta Blockers
por: Liang, Michael, et al.
Publicado: (2009)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts
por: Sorrentino, Andrea, et al.
Publicado: (2022)

Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment
por: Ziff, Oliver J., et al.
Publicado: (2020)

ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?: EDITORIAL to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
por: de Boer, Rudolf A., et al.
Publicado: (2008)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Impact of Beta-blocker, ACE Inhibitor, and ARB therapy on thoracic aorta wall shear stress in bicuspid aortic valve patients
por: McGee, Katherine, et al.
Publicado: (2016)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis
por: Batty, Jonathan A., et al.
Publicado: (2018)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

D-53 | Impact of Cardiovascular Diseases, Calcium Channel Blockers and Beta-Blockers on Mortality of Patients Hospitalized with COVID-19
por: Alhusain, Rashid, et al.
Publicado: (2022)

Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study)
por: Glezer, Maria, et al.
Publicado: (2018)

Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases
por: Jin, Suho, et al.
Publicado: (2020)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
por: Albini, Adriana, et al.
Publicado: (2020)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials
por: Brugts, J. J., et al.
Publicado: (2017)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study
por: Bourke, John P, et al.
Publicado: (2018)

Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease
por: Surma, Stanisław, et al.
Publicado: (2022)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions
por: Albouaini, Khaled, et al.
Publicado: (2007)

Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
por: Ward, Paul R, et al.
Publicado: (2005)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment
por: De Cauwer, Harald
Publicado: (2020)

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
por: Nabilou, Puria, et al.
Publicado: (2022)

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?
por: Manga, Pravin
Publicado: (2020)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020)

Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment for Post Infarct Angina in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries: A MINOCA-BAT Sub Study Rationale and Design
por: Pasupathy, Sivabaskari, et al.
Publicado: (2021)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_htarrslkrjeae3p1h49nssgtgv